<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853030</url>
  </required_header>
  <id_info>
    <org_study_id>FACT Study</org_study_id>
    <nct_id>NCT04853030</nct_id>
  </id_info>
  <brief_title>Fast Advanced Closed-Loop Therapy</brief_title>
  <acronym>FACT</acronym>
  <official_title>A Double-blind, Multinational, Multicentre, Randomised, 2-period Crossover Study to Assess the Efficacy and Safety of Advanced Closed-loop Insulin Delivery With Minimed 670 4.0 System Comparing Faster Insulin Aspart to Standard Insulin Aspart Therapy Over 4 Weeks in Active Children and Adolescents With Type 1 Diabetes - the FACT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ljubljana, Faculty of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Graz Department of Pediatrics and Adolescent Medicine, Graz, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Ljubljana University Children's Hospital Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ljubljana, Faculty of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, multinational, multicenter, randomised, 2-period crossover study to assess&#xD;
      the efficacy and safety of advanced closed-loop insulin delivery with Minimed 670G 4.0 system&#xD;
      comparing Faster Insulin Aspart to Standard Insulin Aspart therapy over 4 weeks in active&#xD;
      children and adolescents with type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Actual">September 20, 2021</completion_date>
  <primary_completion_date type="Actual">September 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinded insulin formulation (Faster and Standard Insulin Aspart)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time above range 180 mg/dl</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>The primary outcomes is a difference in CGM-measured metrics between periods (Minimed 670G 4.0 closed loop with Faster Insulin aspart and Minimed 670G 4.0 closed loop with Standard Insulin aspart) in superiority for proportion of time &gt;180 mg/dL (10.0 mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in range 70-180 mg/dl</measure>
    <time_frame>4 weeks for each arm of the crossover</time_frame>
    <description>CGM derived indices over the study period of each treatment period ((Minimed 670G 4.0 closed loop with Faster Insulin aspart and Minimed 670G 4.0 closed loop with Standard Insulin aspart)) for 24/7 in time in range 70 to 180 mg/dL (3.9 to 10.0 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below range &lt;70 mg/dl</measure>
    <time_frame>4 weeks for each arm of the crossover</time_frame>
    <description>CGM derived indices over the study period of each treatment period ((Minimed 670G 4.0 closed loop with Faster Insulin aspart and Minimed 670G 4.0 closed loop with Standard Insulin aspart)) for 24/7 in time below range 70 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose</measure>
    <time_frame>4 weeks for each arm of the crossover</time_frame>
    <description>CGM derived indices over the study period of each treatment period ((Minimed 670G 4.0 closed loop with Faster Insulin aspart and Minimed 670G 4.0 closed loop with Standard Insulin aspart)) for 24/7 in mean glucose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Minimed 670G 4.0 closed loop with Faster Insulin aspart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimed 670G 4.0 closed loop with Standard Insulin aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fiasp</intervention_name>
    <description>Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)</description>
    <arm_group_label>Minimed 670G 4.0 closed loop with Faster Insulin aspart</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novorapid</intervention_name>
    <description>Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid</description>
    <arm_group_label>Minimed 670G 4.0 closed loop with Standard Insulin aspart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 10 and 18 years of age&#xD;
&#xD;
          -  Type 1 diabetes for at least 6 months&#xD;
&#xD;
          -  Insulin pump user for at least 3 months&#xD;
&#xD;
          -  Total daily dose of insulin &gt;8 units/day&#xD;
&#xD;
          -  Treated with rapid acting insulin analogue&#xD;
&#xD;
          -  Subject/carer is willing to perform at least 2 finger-prick blood glucose measurements&#xD;
             per day&#xD;
&#xD;
          -  Screening HbA1c â‰¤ 11 % (97 mmol/mol) based on analysis from local laboratory&#xD;
&#xD;
          -  Willing to wear glucose sensor&#xD;
&#xD;
          -  Willing to wear closed loop system 24/7&#xD;
&#xD;
          -  The subject is willing to follow study specific instructions&#xD;
&#xD;
          -  The subject/carer is willing to upload pump and CGM data at regular intervals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Physical or psychological disease likely to interfere with normal conduct of the study&#xD;
&#xD;
          -  Untreated coeliac disease or thyroid disease&#xD;
&#xD;
          -  Current treatment with drugs known to interfere with glucose metabolism&#xD;
&#xD;
          -  Participation in another interventional clinical investigation&#xD;
&#xD;
          -  Treated with ultra-rapid acting insulin analogue&#xD;
&#xD;
          -  Known or suspected allergy to insulin&#xD;
&#xD;
          -  Carer's lack of reliable telephone facility for contact&#xD;
&#xD;
          -  Subject's severe visual impairment&#xD;
&#xD;
          -  Subject's severe hearing impairment&#xD;
&#xD;
          -  Medically documented allergy towards the adhesive (glue) of plasters or subject is&#xD;
             unable to tolerate tape adhesive in the area of sensor placement&#xD;
&#xD;
          -  Serious skin diseases located at places of the body corresponding with sensor&#xD;
             insertion sites&#xD;
&#xD;
          -  Sickle cell disease, haemoglobinopathy; or has received red blood cell transfusion or&#xD;
             erythropoietin within 3 months prior to time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Graz Department of Pediatrics and Adolescent Medicine</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Ljubljana University Children's Hospital Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

